New Research: Key Drivers of Growth for Antares Pharma, Infinity Pharma, Inotek Pharma, Hostess Brands, Arconic, and Enterprise Products - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Antares Pharma, Inc. (NASDAQ:ATRS), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), Hostess Brands, Inc. (NASDAQ:TWNK), Arconic Inc. (NYSE:ARNC), and Enterprise Products Partners L.P. (NYSE:EPD) including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ATRS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ATRS

INFI DOWNLOAD: http://Fundamental-Markets.com/register/?so=INFI

ITEK DOWNLOAD: http://Fundamental-Markets.com/register/?so=ITEK

TWNK DOWNLOAD: http://Fundamental-Markets.com/register/?so=TWNK

ARNC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARNC

EPD DOWNLOAD: http://Fundamental-Markets.com/register/?so=EPD

 (You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine  Antares Pharma, Inc. (NASDAQ:ATRS), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), Hostess Brands, Inc. (NASDAQ:TWNK), Arconic Inc. (NYSE:ARNC), and Enterprise Products Partners L.P. (NYSE:EPD) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. All information in this release was accessed October 31, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All amounts in millions (except per share amounts).

-----------------------------------------

ANTARES PHARMA, INC. (ATRS) REPORT OVERVIEW

Antares' Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Antares reported revenue of $13.42 vs $12.23 (down 9.7%), diluted earnings per share -$0.02 vs -$0.04. For the twelve months ended December 31, 2016 vs December 31, 2015, Antares reported revenue of $52.22 vs $45.66 (up 14.4%), diluted earnings per share -$0.16 vs -$0.14. Antares is expected to report earnings on 11/08/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.03. The reported EPS for the same quarter last year was -$0.04.

To read the full Antares Pharma, Inc. (ATRS) report, download it here: http://Fundamental-Markets.com/register/?so=ATRS

-----------------------------------------

INFINITY PHARMACEUTICALS, INC. (INFI) REPORT OVERVIEW

Infinity's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Infinity reported revenue of $0.00 vs $9.47, diluted earnings per share -$0.34 vs $1.05. For the twelve months ended  December 31, 2016 vs December 31, 2015,  Infinity reported revenue of $18.72 vs $109.07 (down 82.8%), diluted earnings per share -$0.61 vs -$2.62. Infinity is expected to report earnings on 11/07/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.21. The reported EPS for the same quarter last year was -$0.39.

To read the full Infinity Pharmaceuticals, Inc. (INFI) report, download it here: http://Fundamental-Markets.com/register/?so=INFI

-----------------------------------------

INOTEK PHARMACEUTICALS CORPORATION (ITEK) REPORT OVERVIEW

Inotek's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Inotek reported diluted earnings per share -$0.24 vs $0.33. For the twelve months ended December 31, 2016 vs December 31, 2015, Inotek reported diluted earnings per share -$1.60 vs -$3.72. Inotek is expected to report earnings on 11/08/2017. The report will be for the fiscal Quarter ending September 2017. The reported EPS for the same quarter last year was -$0.41.

To read the full Inotek Pharmaceuticals Corporation (ITEK) report, download it here: http://Fundamental-Markets.com/register/?so=ITEK

-----------------------------------------

HOSTESS BRANDS, INC. (TWNK) REPORT OVERVIEW

Hostess Brands' Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Hostess Brands reported revenue of $203.18 vs $192.34 (up 5.6%). For the twelve months ended December 31, 2016 vs December 31, 2015, Hostess Brands reported revenue of $727.59 vs $620.82 (up 17.2%). Hostess Brands is expected to report earnings on 11/08/2017. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.13.

To read the full Hostess Brands, Inc. (TWNK) report, download it here: http://Fundamental-Markets.com/register/?so=TWNK

-----------------------------------------

ARCONIC INC. (ARNC) REPORT OVERVIEW

Arconic's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Arconic reported revenue of $3,261 vs $3,234 (up 0.8%), diluted earnings per share $0.43 vs $0.27 (up 59.3%), and dividends per share $0.06 vs $0.09 (down 33.3%). For the twelve months ended December 31, 2016 vs December 31, 2015, Arconic reported revenue of $12,394 vs $12,413 (down 0.2%), diluted earnings per share -$2.31 vs -$0.93, and dividends per share $0.36 vs $0.36 (unchanged).

To read the full Arconic Inc. (ARNC) report, download it here: http://Fundamental-Markets.com/register/?so=ARNC

-----------------------------------------

ENTERPRISE PRODUCTS PARTNERS L.P. (EPD) REPORT OVERVIEW

Enterprise Products' Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Enterprise Products reported revenue of $6,607.6 vs $5,617.8 (up 17.6%), diluted earnings per share $0.30 vs $0.27 (up 11.1%). For the twelve months ended December 31, 2016 vs December 31, 2015, Enterprise Products reported revenue of $23,022.3 vs $27,027.9 (down 14.8%), diluted earnings per share $1.20 vs $1.26 (down 4.8%). Enterprise Products is expected to report earnings on 11/02/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $0.31. The reported EPS for the same quarter last year was $0.30.

To read the full Enterprise Products Partners L.P. (EPD) report, download it here: http://Fundamental-Markets.com/register/?so=EPD

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.